Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?

被引:8
作者
Gamboa, Adriana C. [1 ]
Meyer, Benjamin I. [1 ]
Switchenko, Jeffrey M. [2 ]
Rupji, Manali [2 ]
Lee, Rachel M. [1 ]
Turgeon, Michael K. [1 ]
Russell, Maria C. [1 ]
Cardona, Kenneth [1 ]
Kooby, David A. [1 ]
Maithel, Shishir K. [1 ]
Shah, Mihir M. [1 ]
机构
[1] Emory Univ, Winship Canc Inst, Div Surg Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
关键词
adenocarcinoma; adenosquamous carcinoma; esophageal cancer; esophageal surgery; squamous cell carcinoma; JUNCTIONAL CANCER; CHEMORADIOTHERAPY; SURGERY; CHEMORADIATION; CHEMOTHERAPY;
D O I
10.1002/jso.25990
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Esophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC) have distinct outcomes, treatment strategies, and response profiles to therapy. Adenosquamous carcinoma (ASC) is thought to behave more aggressively than each of its counterparts. The aim of this study is to determine if ASC is best managed as AC or SCC. Methods National Cancer Database (2004-2015) was queried for patients with nonmetastatic esophageal ASC. The analysis was stratified by clinical node-negative (cN0) or clinical node-positive (cN1-3). Treatment was categorized into chemoradiation alone, surgery alone, or preoperative chemoradiation followed by surgery. The primary outcome was 5-year overall survival (OS). Results Among 352 patients, 43% were cN0 (n = 151), 57% were cN1-3 (n = 201) and 55% had chemoradiation alone (n = 194), 15% surgery alone (n = 53), and 30% preoperative chemoradiation (n = 105). Among patients who had preoperative chemoradiation, 20% had pathologic complete response (n = 17). For either cN0 or cN1-3, Charlson-Deyo Comorbidity Index did not differ among the treatment groups (all p > 0.05). On Kaplan-Meier analysis for cN0, treatment with surgery alone had comparable OS to preoperative chemoradiation (47% vs 34%; P = .5) and each had improved OS compared to chemoradiation alone (30%; P = .02; P = .06). On univariate analysis for cN0, clinical T category was not associated with OS. For cN1-3, however, preoperative chemoradiation was associated with improved OS when compared to chemoradiation alone or surgery alone (27% vs 19% vs 0%; P < .001). This persisted when accounting for age and clinical T category (hazard ratio: 0.45; P < .001). Conclusion Esophageal ASC behaves more like AC in response to chemoradiation and survival based on treatment modality. A complete response to chemoradiation is only 20% unlike what has been shown for SCC, where chemoradiation is an acceptable definitive therapy. Esophageal ASC should be managed more like AC.
引用
收藏
页码:412 / 421
页数:10
相关论文
共 28 条
  • [1] Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
    Allum, William H.
    Stenning, Sally P.
    Bancewicz, John
    Clark, Peter I.
    Langley, Ruth E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5062 - 5067
  • [2] *AM COLL SURG, NA CANC DAT
  • [3] Bancewicz J, 2002, LANCET, V359, P1727
  • [4] Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
  • [5] Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis
    Bollschweiler, E.
    Metzger, R.
    Drebber, U.
    Baldus, S.
    Vallbohmer, D.
    Kocher, M.
    Holscher, A. H.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (02) : 231 - 238
  • [6] Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis
    Chan, Kelvin K. W.
    Saluja, Ronak
    Delos Santos, Keemo
    Lien, Kelly
    Shah, Keya
    Cramarossa, Gemma
    Zhu, Xiaofu
    Wong, Rebecca K. S.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (02) : 430 - 437
  • [7] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    Cunningham, David
    Allum, William H.
    Stenning, Sally P.
    Thompson, Jeremy N.
    Van de Velde, Cornelis J. H.
    Nicolson, Marianne
    Scarffe, J. Howard
    Lofts, Fiona J.
    Falk, Stephen J.
    Iveson, Timothy J.
    Smith, David B.
    Langley, Ruth E.
    Verma, Monica
    Weeden, Simon
    Chua, Yu Jo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20
  • [8] Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO
  • [9] 2-2
  • [10] Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials
    Donohoe, Claire L.
    Reynolds, John V.
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 : S697 - S704